Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Saved in:
| Title: | Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. |
|---|---|
| Authors: | Helsby N; Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. n.helsby@auckland.ac.nz., Yong M; Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand., Burns K; Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand., Findlay M; Cancer Trials New Zealand, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.; Auckland Regional Cancer and Blood Service, Auckland City Hospital, Grafton, Auckland, New Zealand., Porter D; Auckland Regional Cancer and Blood Service, Auckland City Hospital, Grafton, Auckland, New Zealand. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Sep; Vol. 88 (3), pp. 533-542. Date of Electronic Publication: 2021 Jun 10. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
